Clinical trial NCT03769467: Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Official title: An Open-Label Phase 1B/2 Study to Evaluate the Safety and Efficacy of Tabelecleucel in Combination With Pembrolizumab in Subjects With Platinum-pretreated, Recurrent/Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Nasopharyngeal Carcinoma
Nasopharyngeal Neoplasms
Epstein-Barr Virus Infections
Epstein-Barr Viraemia
Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Keywords: Nasopharyngeal Carcinoma (NPC)
NPC
Nasopharyngeal Cancer
Nose Cancer
Epstein-Barr Virus (EBV)
Epstein-Barr Virus Viremia
EBV-associated NPC
Allogeneic, off-the-shelf T-cell
immunotherapy
Head and Neck Cancer
Carcinoma
Nasopharyngeal Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Pharyngeal Neoplasms
Otorhinolaryngologic Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Nasopharyngeal Diseases
Pharyngeal Diseases
Stomatognathic Diseases
Otorhinolaryngologic Diseases
Pembrolizumab
Programmed death-1 (PD-1)
Programmed death-ligand 1(PD-L1)
Lead sponsor: Atara Biotherapeutics
Sponsor class: INDUSTRY
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2018-12-07
Enrollment: 12
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a multicenter, open-label, single-arm Phase 1B/2 study to assess the safety and efficacy of tabelecleucel in combination with pembrolizumab for the treatment of subjects with platinum-pretreated, recurrent/metastatic Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC).

Detailed description: This is a multicenter, open-label, single-arm Phase 1B/2 study to assess the safety and efficacy of tabelecleucel in combination with pembrolizumab for the treatment of subjects with platinum-pretreated, recurrent/metastatic EBV+ NPC.

Tabelecleucel will be selected for each subject from the bank of available tabelecleucel cell products based on matching ≥ 2 human leukocyte antigen (HLA) alleles, at least one of which is a restricting HLA allele, shared between the tabelecleucel donor and the subject's EBV+ NPC. Sites will provide high resolution HLA typing of the subject and other information as required by the protocol.

Phase 1B will identify the maximum tolerated dose (MTD) and characterize the dose limiting toxicity (DLT) for tabelecleucel in combination with pembrolizumab in up to 24 subjects. In the absence of an MTD, the recommended Phase 2 dose (RP2D) will be identified. Phase 2 will evaluate the safety and efficacy of the combination in 36 subjects at the recommended dose level from Phase 1B.

Eligibility criteria: Inclusion Criteria:

1. Male or female ≥ 12 years of age.
2. Incurable, locally recurrent or metastatic Epstein-Barr virus (EBV)+NPC (World Health Organization type II/III) in whom the EBV nucleic acid or antigens have been demonstrated in tissue biopsy samples.
3. Subjects must have had prior receipt of platinum-containing regimen either:

   1. For the treatment of recurrent or metastatic disease, or
   2. Experienced progression of disease within 6 months following completion of a platinum-based combination therapy as part of (neo)adjuvant chemotherapy. Note: Subject who had only concurrent chemoradiation therapy without (neo)adjuvant therapy and then recurred/metastasized must have progressed on at least 1 platinum-containing regimen for their recurrent/metastatic disease before study entry.
4. Phase 1B (Cohort 1):

   1. Checkpoint inhibitor naïve (have never received pembrolizumab or any other anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-OX40 or anti-CTLA-4 antibodies) OR
   2. Refractory to an anti-programmed cell death protein-1 (PD-1) or anti-programmed death-ligand1 (PD-L1) monoclonal antibody approved by the local regulatory agency either as monotherapy or in combination with other checkpoint inhibitors or therapies according to their approved label. To be considered refractory to an anti-PD-1 or anti-PD-L1 monoclonal antibody, all of the following criteria must be met:

   i. Received at least 2 doses of anti-PD-1 or anti-PD-L1 monoclonal antibody at a local regulatory agency-approved dose and schedule. ii. Have progressive disease after anti-PD-1 or anti-PD-L1 monoclonal antibody as defined according to Response Evaluation Criteria in Solid Tumors) RECIST 1.1. The initial evidence of progressive disease is to be confirmed by a second assessment, no less than 4 weeks from the date of the first documented progressive disease, in the absence of rapid clinical progression. (The eligibility determination will be made by the investigator and then the sponsor will collect for retrospective analysis at a central vendor. Once progressive disease is confirmed, the initial date of progressive disease documentation will be considered the date of disease progression).

   iii. Documented disease progression within 24 weeks of the last dose of anti-PD-1 or anti-PD-L1 monoclonal antibody. A subject who was re-treated with anti-PD-1 or anti-PD-L1 monoclonal antibody and a subject who was on maintenance with an anti-PD-1 or anti-PD-L1 monoclonal antibody will be allowed to enter the study as long as there is documented PD within 24 weeks of the last treatment date (with the anti-PD-1 or anti-PD-L1 monoclonal antibody).
5. Phase 1B (Cohort 1): If PD-1/PD-L1 failure (ie, refractory to or relapsed after PD-1/PD-L1 treatment), must have a lesion that can be biopsied after administration of tabelecleucel with acceptable clinical risk (as judged by the investigator) and must agree to undergo biopsy before Cycle 1 Day 1.
6. Phase 2 (Cohort 2): Checkpoint inhibitor naïve (have never received pembrolizumab or any other anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-OX40 or anti-CTLA-4 antibodies).
7. For all subjects: Agree to submit prior biopsy material, if available, for biomarker assessment.
8. Life expectancy ≥ 4 months at time of screening.
9. Measurable disease using RECIST 1.1. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been documented in such lesions.
10. Eastern Cooperative Oncology Group (ECOG) performance status of \< 2 for subjects aged \> 16 years; Lansky score ≥ 70 for subjects aged 12 to 16 years.
11. Adequate organ function per the protocol.
12. Willing and able to provide written informed consent (pediatric subjects 12 to \< 18 years of age must provide assent along with consent from the subject's legally authorized representative).

Exclusion Criteria:

1. Disease that is suitable for local therapy administered with curative intent.
2. Requires vasopressor or ventilator support.
3. Received antithymocyte globulin or similar anti-T-cell antibody therapy ≤ 4 weeks prior to Cycle 1 Day 1.
4. Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to Cycle 1 Day 1 of study treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the sponsor's medical monitor.
5. Active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
6. History or evidence of interstitial lung disease.
7. History of severe hypersensitivity (Grade ≥ 3) to pembrolizumab and/or any of its excipients.
8. Active infection requiring systemic therapy.
9. History of (non-infectious) pneumonitis that required steroids or current pneumonitis.
10. Received transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (including granulocyte-colony stimulating factor, granulocyte macrophage-colony stimulating factor or recombinant erythropoetin) within 4 weeks prior to study Day 1.
11. Unresolved immunotherapy-related AEs or treatment for these events within 4 weeks prior to enrollment.
12. History of severe immunotherapy-related adverse effects (Common Terminology Criteria for Adverse Events \[CTCAE\] grade 4 or CTCAE grade 3 requiring treatment \> 4 weeks).
13. Received any non-oncology vaccine therapy used for prevention of infectious diseases for up to 30 days prior to enrollment. Examples include, but are not limited to: measures, mumps, rubella, chicken pox, yellow fever, rabies, bacille Calmette-Guerin, and typhoid vaccine. Seasonal flu vaccines that do not contain live virus are acceptable.
14. Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
15. Pregnancy or breastfeeding: females of childbearing potential must have a negative serum pregnancy test. The serum pregnancy must be confirmed negative within 72 hours of Cycle 1 Day 1 (first dose of investigational product) for the subject to be eligible.
16. Female of childbearing potential or male with a female partner of childbearing potential unwilling to use a highly effective method of contraception (abstinence is acceptable) for the course of the study through 120 days after the last study dose.
17. Inability to comply with study procedures.
18. Received chemotherapy or targeted small molecule therapy within 2 weeks of Cycle 1 Day 1. Subjects must have recovered (ie, grade ≤ 1 or at baseline) from adverse events (AEs) due to a previously administered agent. Subjects with grade ≤ 2 neuropathy or grade ≤ 2 alopecia are an exception to this criterion.
19. Received prior radiotherapy within 2 weeks of Cycle 1 Day 1. Subjects must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1- week washout is permitted for palliative radiation (≤ 2 weeks of radiotherapy) to non-central nervous system (CNS) disease.
20. Antibody/biologic therapy within 4 weeks of Cycle 1 Day 1 or not recovered (i.e., grade ≤ 1 or at baseline) from AEs due to agents administered more than 4 weeks earlier.
21. Carcinomatous meningitis; and/or active CNS metastases, unless metastases are treated and stable and the subject does not require systemic steroids. NOTE: Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging \[using the identical imaging modality for each assessment, either magnetic resonance imaging (MRI) or computed tomography (CT) scan\] for at least four weeks prior to the first dose of investigational product and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to first dose of investigational product. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
22. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
23. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
24. Known history of human immunodeficiency virus (HIV), known active hepatitis B virus (HBV; e.g., hepatitis B surface antigen \[HBsAg\] reactive), or hepatitis C virus (HCV; e.g., HCV ribonucleic acid \[RNA\] is detected).
25. Prior treatment with any investigational product within 4 weeks of Cycle 1 Day 1.
26. Prior treatment with EBV T cells.

Primary outcomes:
measure: Cohort 1B: Number of Participants With Dose-Limiting Toxicities (DLTs)
timeFrame: From Day 1 through Day 21 of Cycle 1
measure: Cohort 1B: Maximum Tolerated Dose (MTD)
timeFrame: From Day 1 through Day 21 of Cycle 21
measure: Cohort 1B: Recommended Phase 2 Dose (RP2D) of Tabelecleucel in Combination With Pembrolizumab
timeFrame: From Day 1 through Day 21 of Cycle 1
measure: Cohort 1B: Characterization of the Safety Profile: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
timeFrame: From Day 1 to end of study (1 year after the last dose or until disease progression, whichever occurred first) (approximately 27 months)
measure: Cohort 2: Characterization of the Safety Profile: Number of Participants With TEAEs and TESAEs
timeFrame: From Day 1 to end of study (1 year after the last dose or until disease progression, whichever occurred first) (approximately 27 months)
measure: Cohort 2: Objective Response Rate (ORR)
timeFrame: From Day 1 to end of study (1 year after the last dose or until disease progression, whichever occurred first) (approximately 27 months)
Secondary outcomes:
measure: Cohort 2: Complete Response (CR) Rate
timeFrame: From Day 1 to end of study (1 year after the last dose or until disease progression, whichever occurred first) (approximately 27 months)
measure: Cohort 2: Duration of Response (DOR)
timeFrame: From Day 1 to end of study (1 year after the last dose or until disease progression, whichever occurred first) (approximately 27 months)
measure: Cohort 2: Progression Free Survival (PFS)
timeFrame: From Day 1 to end of study (1 year after the last dose or until disease progression, whichever occurred first) (approximately 27 months)
measure: Cohort 2: Overall Survival (OS)
timeFrame: From Day 1 to end of study (1 year after the last dose or until disease progression, whichever occurred first) (approximately 27 months)
measure: Cohort 2: Immune Response Rate (iRR)
timeFrame: From Day 1 to end of study (1 year after the last dose or until disease progression, whichever occurred first) (approximately 27 months)
measure: Cohort 2: Duration of Immune Response (DOiR)
timeFrame: From Day 1 to end of study (1 year after the last dose or until disease progression, whichever occurred first) (approximately 27 months)
Other outcomes:
Locations:
city: Duarte
country: United States
facility: City of Hope
state: California
city: Palo Alto
country: United States
facility: Stanford Hospital and Clinics
state: California
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Morristown
country: United States
facility: Atlantic Health System / Morristown Medical Center
state: New Jersey
city: New York
country: United States
facility: Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
state: New York
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
city: Philadelphia
country: United States
facility: University of Pennsylvania (Adults and Pediatrics)
state: Pennsylvania
Study officials:
affiliation: Atara Biotherapeutics
name: Aditi Mehta, DO
role: STUDY_DIRECTOR
References: